<DOC>
	<DOCNO>NCT01187888</DOCNO>
	<brief_summary>The purpose study determine whether rasagiline effective treatment Progressive Supranuclear Palsy ( PSP ) , rapidly progress disease symptomatology similar Parkinson 's Disease . The major aim study limitation halt process neurodegeneration influence postural instability .</brief_summary>
	<brief_title>Efficacy , Tolerability Safety Azilect Subjects With Progressive Supranuclear Palsy</brief_title>
	<detailed_description>Progressive Supranuclear Palsy ( PSP ) rapidly progress disease median survival onset symptom 5.8 years.PSP characterize early fall , vertical ophthalmoparesis , akinetic-rigid feature , prominent bulbar dysfunction fronto-subcortical dementia . So far treatment disease negative outcome vast majority study make impossible set standard . As majority patient experience severe fall vertigo already early phase disease , drug desire would able slow disease progression special focus postural instability exert neuroprotective effect . The monoamino oxidase inhibitor Rasagiline might able influence progression PSP .</detailed_description>
	<mesh_term>Paralysis</mesh_term>
	<mesh_term>Supranuclear Palsy , Progressive</mesh_term>
	<mesh_term>Rasagiline</mesh_term>
	<criteria>Clinical sign Progressive Supranuclear Palsy ( PSP ) . Diagnosis make patient clinical probable PSP ( Litvan et al. , 1996 ) . Patients include PSP stage &lt; /= II ( Golbe et al. , 1997 ) , least PSPRS &lt; 40 ( Golbe et al. , 2007 ) accord diagnostic criterion resume Neuroprotection Natural History Parkinson Plus Syndromes ( NNIPPS ) trial ( Bensimon et al. , 2009 ) Patients , male female , age 50 80 year Subjects whose clinical condition time enrolment require low [ &lt; /= 500 mg /day ] stable dose L3,4Dihydroxyphenylalanine ( LDOPA ) least 2 week prior study entry Capability willingness give write sign date informed consent document indicate subject inform pertinent aspect study No clinically probable PSP No write inform consent possible Age &gt; 80 &lt; 50 year Dementia ( MiniMental State Examination [ MMSE ] &lt; /= 24 ) Subjects clinically significant psychiatric illness , include major depression Subjects take experimental drug within 60 day prior baseline Subjects use sympathomimetics ( include overthecounter remedy nasal oral ) , dextromethorphan , pethidine St. John 's wort within 7 day prior baseline . Loss postural reflex ( independent walk possible , inability stand unassisted , wheelchairbound ) Feeding tube / recommendation feed tube Unintelligible speech History brain disease ( e.g . repeat stroke , cerebral tumour , hydrocephalus ) 1methyl4phenyl1,2,5,6tetrahydropyridine ( MPTP ) exposure Oculogyric crisis Early severe autonomic failure Systemic disorder affect brain Women postmenopausal ( e.g . one year without menstrual period ) surgically sterilize . Known history hypersensitivity investigational drug drug similar chemical structure Subjects used antidepressant , include selective serotonin reuptake inhibitor , tricyclic tetracyclic antidepressant ( except amitriptyline &lt; = 50 mg/day , trazodone &lt; = 100 mg/day , citalopram &lt; = 20 mg/ day , sertraline &lt; = 100 mg/day paroxetine &lt; = 30 mg/day , escitalopram &lt; = 10 mg/day ) within 42 day prior baseline Subjects use drug know involved drug interaction via inhibition hepatic Cytochrome P450 1A2 ( CYP 1A2 ) within 30 day prior baseline ( cimetidine , ciprofloxacin , clarithromycin , enoxacin , erythromycin , fluvoxamine , isoniazide , nalidixic acid , norfloxacin , troleandomycin , zileuton ) Subjects use Monoamine oxidase ( MAO ) inhibitor include reserpine methyldopa within three month prior baseline Antiemetic antipsychotic medication central dopamine antagonist activity ( except quetiapine fumarate ) within six month prior baseline Participation clinical trial within last 30 day prior study start Unstable antiparkinsonian medication within 30 day baseline Previous use Rasagiline Selegiline Subjects clinically significant unstable medical surgical condition may preclude safe complete study participation ( base investigator 's judgment ) . Such condition might include cardiovascular , vascular disease , pulmonary , hepatic impairment ( ChildPugh score &gt; 5 ) , renal , metabolic disease malignancy determine medical history , physical examination , laboratory test , ECG</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>PSP</keyword>
	<keyword>Progressive Supranuclear Palsy</keyword>
	<keyword>Rasagiline</keyword>
	<keyword>Azilect</keyword>
	<keyword>PROSPERA</keyword>
</DOC>